Ann-Louice Bruhn

About Ann-Louice Bruhn

Global leader in Market Access, Pricing, and Commercial Strategy, launching 10+ New Molecular Entities (NMEs) and 20+ indications; and owning P&L responsibility across Oncology, Hematology, Immunology, and Rare Diseases. Builds integrated strategies that accelerate patient access, expand global market reach, drive commercial growth, and secure executive-level endorsement for enterprise-critical initiatives—Trilingual in English, Swedish, and Danish. STRATEGIC MARKET ACCESS & PRICING LEADERSHIP Directed global and U.S. access and pricing strategies for 10 NMEs and 20+ indications across oncology, hematology, immunology, and rare diseases. Developed payer frameworks enabling rapid launch readiness and reimbursement in complex markets, including the U.S, EU, China, and APAC. CROSS-FUNCTIONAL ALIGNMENT & INFLUENCE Integrated HTA/payer insights into R&D and brand planning to shape evidence, cross-functional market eco-system engagement plans, and commercialization strategy. Established a global center of excellence for access, engaging 200+ leaders through scalable knowledge-sharing platforms. Secured CEO-level endorsement for portfolio strategies and go/no-go decisions impacting over 50% of BMS’s immuno-oncology revenue.LAUNCH EXCELLENCE & COMMERCIAL IMPACT Increased U.S. sales of Reblozyl® by 60% in 3 months from the launch of the Myeloid Dysplastic syndrome. Achieved 18-month acceleration of Opdivo® in adjuvant melanoma and delivered premium pricing outcomes with innovative market access and evidence strategy. Digital Patient engagement and real-world data strategy.STRATEGY & SOLUTION DESIGN Thrives in ambiguity, creating frameworks for uncharted territories, including pipeline assets and LMIC markets. Translates complex scientific, regulatory, and policy insights into asset and market-shaping strategies. Pioneered China’s first BMS reimbursement approval through adaptive access strategy, and stakeholder engagement. ENTREPRENEURSHIP & THOUGHT PARTNERSHIP Founded ADASTRA Partners to advise biotech and health tech start-ups on U.S. market entry, pricing, and investor value strategy. Mentor and lecture for innovation incubators, equipping emerging entrepreneurs with critical knowledge of the U.S. healthcare system.COLLABORATIVE LEADERSHIP & ENGAGEMENT Recognized as a trusted advisor and thought partner, driving collaboration across medical, commercial, policy, and payer ecosystems. VALUES Collaboration | Impact | Integrity | Patient-Centricity

Experience

1. Patient Engagement and Integration Strategy

   Ezscript

   Jan 2025 — Present

Education

• Lund University

  Nursing

• Stockholm School of Economics

  Master of Business Administration - MBA, Business Administration and Management, Entrepreneurship and Health Policy

• Columbia Business School

  Leadership: Lead Engage Accelerate Develop (LEAD)

  2018

• Kalmar University

  Master of Science - MS